FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Delayed Börse Stuttgart 12:15:07 01/07/2024 pm IST | ||
| 116.2 EUR | -0.24% |
|
| Current month | +35.22% | ||
| 1 month | +40.05% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 01/24/01 | 116.2 | -0.24% |
| 28/24/28 | 116.4 | -1.63% |
| 27/24/27 | 118.4 | -4.76% |
| 26/24/26 | 124.3 | +1.92% |
| 25/24/25 | 121.9 | +11.20% |
Delayed Quote Börse Stuttgart
Last update July 01, 2024 at 12:15 pm IST
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MA9T8S |
| ISIN | DE000MA9T8S4 |
| Date issued | 02/11/2021 |
| Strike | 804.9 kr |
| Maturity | Unlimited |
| Parity | 0.23 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 124.3 € |
|---|---|
| Lowest since issue | 2.89 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Certificates
- Certificat
